MedDataX Logo

HUSH Restriction in HIV Infected Patients

NCT ID: NCT04172480

Last Updated: 2021-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-01

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

HIV eradication faces a major obstacle that is viral persistence in latent reservoir cells despite antiretroviral therapy. Epigenetic repression plays a central role in viral transgene latency and several epigenetic regulators have been involved in this process. Among them, the "Human Silencing Hub" or HUSH complex, composed of Tasor, MPP8 and periphilin, has been shown to recruit the H3K9me3 methyltransferase "SET domain bifurcated 1" (SETDB1) and is therefore responsible for genes' epigenetic repression. Our recent results highlight the ability of Vpx from HIV-2/SIVsmm to counteract HUSH and to reactivate latent viruses in a latency model. We propose here to study HUSH activity along pathogenesis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

acute HIV1 infection

Patient infected by HIV1, prior treatment initiation

Blood sampling

Intervention Type OTHER

Peripheral blood sampling on EDTA

chronic HIV1 infection

Patient infected by HIV1, untreated or without treatment since at least 3 months

Blood sampling

Intervention Type OTHER

Peripheral blood sampling on EDTA

HIV2 infection

Patient infected by HIV2, untreated or without treatment since at least 3 months

Blood sampling

Intervention Type OTHER

Peripheral blood sampling on EDTA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sampling

Peripheral blood sampling on EDTA

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Symptomatic or asymptomatic acute HIV1 infection
* Age above 15 years old
* No ARV treatment prior inclusion (excepted as prophylaxis pre or post exposure)


* Chronic HIV1 infection
* Age above 18 years old
* No ARV treatment since at least 3 month (regardless the reason)


* HIV2 Infection
* Age above 18 years old
* No ARV treatment since at least 3 month (regardless the reason)

Exclusion Criteria

* HIV1 and HIV2 co-infection
* Evolutive intercurrent pathology, in particular active co-infection (i.e. HBV, HCV, tuberculosis, HTLV1)
* Life-threatening pathology
Minimum Eligible Age

15 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ANRS, Emerging Infectious Diseases

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Bicêtre

Le Kremlin-Bicêtre, , France

Site Status NOT_YET_RECRUITING

Hôtel-Dieu

Paris, , France

Site Status RECRUITING

Hôpital Necker

Paris, , France

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Antoine CHERET, MD

Role: primary

Jean-Paul VIARD, Pr

Role: primary

Claudine DUVIVIER, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ANRS RF 004

Identifier Type: -

Identifier Source: org_study_id